Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann M Buchanan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 24, 2025
Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b TrialThanyawee Puthanakit, Linda Aurpibul, Monica Lopez, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
Tropical Medicine & International Health : TM & IH|July 20, 2010
Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro RegionAnn M Buchanan, Florida J Muro, Jean Gratz, et al.
AIDS Research and Human Retroviruses|August 12, 2017
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern TanzaniaDorothy E Dow, Werner Schimana, Balthazar M Nyombi, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsHelena Rabie, Dwight E Yin, Shawn Ward, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
The Lancet. HIV|August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation studyKristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 24, 2025
Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b TrialThanyawee Puthanakit, Linda Aurpibul, Monica Lopez, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
Tropical Medicine & International Health : TM & IH|July 20, 2010
Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro RegionAnn M Buchanan, Florida J Muro, Jean Gratz, et al.
AIDS Research and Human Retroviruses|August 12, 2017
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern TanzaniaDorothy E Dow, Werner Schimana, Balthazar M Nyombi, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsHelena Rabie, Dwight E Yin, Shawn Ward, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
The Lancet. HIV|August 4, 2023
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation studyKristina M Brooks, Jennifer J Kiser, Lauren Ziemba, et al.
Pageof 3